文献速递间质性肺疾病

抗纤维化药物与肺移植:西班牙多中心病例对照研究

Antifibrotics and lung transplantation: A Spanish multicentre case-controlled study.
PubMed 文献 · Respirology · 2022-08-28

该研究回顾性纳入2015年1月至2019年6月在西班牙四家肺移植专科医院接受肺移植的IPF患者,比较移植时使用抗纤维化药物者(103例)与未使用者(61例)的移植相关结局。两组胸壁裂开发生率无差异,但用药组出现更早;两组总体移植后生存无差异,但对照组1年生存显著更高。

要点

  • 抗纤维化治疗不增加胸壁裂开发生率,但裂开出现时间更早(21天 vs 63天)。
  • 两组总体移植后生存及30天、90天、3年、5年条件生存无差异。
  • 对照组1年生存显著高于抗纤维化组(93.3% vs 80.6%)。

核心结论

  • 有证据表明使用抗纤维化药物的IPF患者移植后胸壁裂开出现更早,但该因素未显著影响生存。
  • 两组总体移植后生存无差异,但对照组1年生存显著更高。

研究设计与样本

  • 西班牙四家肺移植专科医院的回顾性多中心病例对照研究。
  • 共纳入164例IPF肺移植患者,其中病例组103例(移植时接受抗纤维化治疗),对照组61例(未接受),按1:1匹配设计。

主要发现

  • 两组胸壁裂开发生率无差异(12.3% vs 13.7%;p = 0.318)。
  • 使用抗纤维化药物者胸壁裂开出现更早(21天[IQR = 12.5-41.5] vs 63天[IQR = 46.75-152.25];p = 0.012)。
  • 两组总体移植后生存无差异(p = 0.698),30天、90天、3年、5年条件生存亦无差异。
  • 对照组1年生存显著高于抗纤维化组(93.3% vs 80.6%;p = 0.028)。

临床怎么用

  • IPF患者肺移植围术期使用抗纤维化药物时,应关注胸壁裂开可能更早出现。
  • 抗纤维化治疗不构成移植后总体生存的显著不良因素,但需注意1年生存差异。

局限性

  • 回顾性病例对照设计,样本量有限(164例),可能存在选择偏倚与混杂。
  • 仅纳入西班牙四家中心,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Antifibrotic drugs are the standard treatments for patients with idiopathic pulmonary fibrosis (IPF). This study aims to assess the safety of antifibrotic treatment in IPF patients undergoing lung transplantation. METHODS: Patients with a diagnosis of IPF who received a lung transplant between January 2015 and June 2019 at four Spanish hospitals specialized in lung transplantation were retrospectively recruited. Cases were defined as patients receiving antifibrotic treatments at time of transplant. Each case was matched with a control who did not receive antifibrotic treatment. RESULTS: A total of 164 patients were included in the study cohort (103 cases and 61 controls). There were no statistically significant differences between the cases and controls in any of the items studied related to transplantation except the time until the appearance of chest wall dehiscence: although there were no differences in the incidence of wall dehiscence in either group (12.3% vs. 13.7%; p = 0.318), the patients on antifibrotic drugs experienced it earlier (21 days [IQR = 12.5-41.5] vs. 63 days [IQR = 46.75-152.25]; p = 0.012). There were no differences in overall post-transplant survival between the two groups (p = 0.698) or in conditional survival at 30 days, 90 days, 3 years or 5 years. However, 1 year survival was significantly greater among controls (80.6% vs. 93.3%; p = 0.028). CONCLUSION: There was evidence that chest wall dehiscences appeared earlier post-transplant in patients using antifibrotics, even though this factor did not significantly impact survival.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Mora Cuesta VM, Iturbe Fernández D, Aguado Ibáñez S, et al. Antifibrotics and lung transplantation: A Spanish multicentre case-controlled study. Respirology. 2022. PMID: 36053911. doi:10.1111/resp.14352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。